We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF

136 hedge funds and large institutions have $528M invested in VanEck Pharmaceutical ETF in 2025 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8% less capital inflows, than outflows

Capital inflows: $174M | Capital outflows: $190M

4% less funds holding

Funds holding: 142 → 136 (-6)

9.64% less ownership

Funds ownership: 87.52% → 77.88% (-9.6%)

28% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 25

29% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 51

97% less call options, than puts

Call options by funds: $1.67M | Put options by funds: $64.7M

Holders
136
Holders Change
-6
Holders Change %
-4.23%
% of All Funds
1.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
18
Increased
36
Reduced
51
Closed
25
Calls
$1.67​M
Puts
$64.7​M
Net Calls
-⁠$63.1​M
Net Calls Change
-⁠$59.9​M

PPH Hedge Fund Activity: Q1 2025 in Review

136 of the 7,490 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2025, worth a combined $528M — up 2.8% from $514M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of PPH and 18 opened new positions — a net loss of 7 holders — while 51 trimmed existing stakes and 36 added.

The largest buyer was Fisher Asset Management, opening a new position worth an estimated $115M. The largest seller was Goldman Sachs, cutting an estimated $102M.

  • 136 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2025, down from 142 in Q4 2024.
  • Funds reported $528M of VanEck Pharmaceutical ETF stock for Q1 2025, up 2.8% quarter-over-quarter.
  • 18 funds opened new VanEck Pharmaceutical ETF positions in Q1 2025 and 25 closed out, a net change of -7 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q1 2025 was Fisher Asset Management, an estimated $115M added.
  • The largest VanEck Pharmaceutical ETF seller in Q1 2025 was Goldman Sachs, an estimated $102M sold.

Based on aggregated 13F filings for Q1 2025.